地塞米松辅助治疗慢性阻塞性肺疾病并发社区获得性肺炎的回顾性分析

摘要

Objective To explore the effects of adjunctive treatment with dexamethasone on patientswith chronic obstructive pulmonary disease(COPD)and community-acquired pneumonia(CAP).Methods 83 inpatients with confirmed COPD and CAP were collected.According to whether they weretreated with dexamethasone,they were allocated 38 to the dexamethasone treated group and 45 to the controlgroup.The dynamic changes of serum levels of C-reactive protein(CRP),procalcitonin(PCT),and theclinical effecacy were compared.Results The level of CRP in the dexamethasone treatment group wassignificantly lower than that of the control group after treatment in the first 5-7 days(P <0.01).Patientson the dexamethasone group had faster defervescence compared with control group(P <0.05).Medianlength of stay was shorter in the treatment group compared with control group(P <0.05).Conclusion Inpatients with COPD and CAP,adjunctive treatment with dexamethasone may inhibit early inflammatory responses,improve clinical symptoms and shorten length of stay.%目的：探讨地塞米松辅助治疗慢性阻塞肺疾病（COPD）并发社区获得性肺炎（CAP）的疗效。方法将83例 CAP 住院患者根据入院后是否使用地塞米松分为治疗组38例和对照组45例，比较两组治疗期间血清 C 反应蛋白（CRP）、降钙素原（PCT）动态变化及临床疗效。结果治疗组治疗后第5～7天 CRP 水平明显低于对照组（P ＜0．01）；治疗组与对照组比较，体温恢复时间快（P ＜0．05）、住院时间短（P ＜0．05）。结论地塞米松辅助治疗 COPD 并发 CAP 可早期抑制机体炎症反应及改善临床症状，缩短住院时间。